

ANTEO INITIATES LITHIUM-ION BATTERY DEVELOPMENT PROJECT

19 December 2017

Highlights:

- US based battery consulting company, Polaris Battery Labs LLC, to commence development project of the Company's Nano-coating Technology (AnteoCoat) on Lithium-ion batteries
- Project to produce data package using half-cell and full-cell prototype batteries incorporating the AnteoCoat technology with the objective to increase the commercial value of our battery IP and stimulate further discussions with battery manufacturers

Anteo Diagnostics Ltd (ASX: ADO) ("**Anteo**" or "**Company**") has engaged US based battery consulting company Polaris Battery Labs LLC ("**Polaris**") to commence a development project on its Nano-coating Technology ("**AnteoCoat**") for use in Lithium-ion batteries.

The primary objective of the project is to leverage Anteo's existing proof of concept results and to generate third party (Polaris) data that demonstrates the effects of AnteoCoat on the performance of Lithium-ion battery cells.

The development project will examine the impact of various concentrations of AnteoCoat on a variety of ratios of Silicon incorporated into an anode. The project will also examine the performance of AnteoCoat on half-cell and full-cell battery prototypes. The final aspect of the work to be undertaken will be the modelling of these results such that the overall impact of AnteoCoat on Lithium-ion anode battery performance can be fully characterised and documented. It is expected that the generated results will provide a basis for understanding the impact of AnteoCoat on other components of Lithium ion batteries such as the battery cathode.

This is a 6 month project and it is anticipated that a comprehensive data package will be generated by June 2018. The data package that is produced will provide Anteo with sufficient material to continue discussions with battery manufacturers.

The Company's incoming CEO, Dr Stefan Enderling, stated, "Our team is impressed by Polaris's comprehensive testing facility, team and partner network. We are excited to work with Polaris on this project and expect the data to play an important part in our commercialisation strategy for AnteoCoat. The devised project allows us to understand the performance impact of AnteoCoat on silicon based Lithium-ion batteries. Once this project is completed we expect to be in a position to further progress discussions with battery manufacturers. It is important to note that there are likely to be further studies required on full-cell batteries to provide an understanding of how our product can be commercialised into existing battery technologies and production processes."

ABOUT POLARIS BATTERY LABS LLC

Polaris Battery Labs is a US based sample making and test lab for Lithium ion batteries. Their goal: to accelerate commercialization of new technologies by offering lab facilities, advisory services, and more to developers and start-up companies.

Polaris assists companies in moving through four phases of bringing battery products to market:

- I. Proof-of-concept
- II. Prototyping
- III. Toll coating
- IV. Mass production

The Polaris business model is to assist companies to identify original equipment manufacturers wishing to incorporate new technologies into their consumer, vehicle, and industrial battery products through its existing network of battery industry relationships.

ABOUT ANTEO GROUP – Anteo Diagnostics Limited (ADO:ASX) & Subsidiaries

Anteo Group is a global nanochemistry technology and medical supply group, developing, commercialising, manufacturing and distributing products for the life sciences, clinical diagnostics and bioseparations markets, and creating new applications in the energy and medical devices sectors.

Through Anteo Technology, the Anteo Group owns a patented nanochemistry surface engineering technology which unites the strength and stability of covalent binding with the gentleness of passive binding through multi-point chelation. Through the use of its reagents binders, coatings or primers, Anteo provides materials and services for high-value commercial applications. Markets include protein binding and antibody coupling (e.g. point of care devices), primers for in-vivo medical devices and medical drug delivery, and coatings with commercial applications across a broad range of industry sectors, including life sciences, in vitro diagnostics, medical devices and energy.

For more information, please visit www.anteodx.com